Twenty-five years running global regulatory and quality functions inside some of medical technology’s largest companies gives a person a particular vantage point: they’ve watched an industry’s compliance infrastructure evolve in real time, through mergers, product recalls, changing FDA frameworks and now the arrival of artificial intelligence into a field that has always prized caution over speed. Jessica Smith, PhD, spent that career leading regulatory affairs and quality organizations at Integra LifeSciences, Becton Dickinson, Hillrom and C. R. Bard. This month, the Salt Lake City-based executive announced a shift in focus, moving from corporate leadership into mentorship and advisory work, aimed at passing that vantage point directly to the next generation of regulatory and quality professionals.
Smith’s executive career centered on functions that rarely get public attention but carry outsized consequences when they fail: global regulatory submissions, product registrations, post-market compliance and the enterprise quality systems that keep multinational medtech portfolios audit-ready. Beyond those core responsibilities, she also led organizational transformation work, M&A due diligence and the buildout of quality systems designed to scale across large global product lines, the connective infrastructure that determines whether a medical device company can actually integrate an acquisition rather than just complete one on paper.
That background traces back to an unusually multidisciplinary education. Smith earned both a Master of Engineering and a PhD in Bioengineering from the University of Utah, after beginning her professional path in civil engineering before moving into bioengineering, regulatory affairs and eventually quality assurance. That trajectory, technical training reshaped into strategic and organizational leadership, is a pattern regulatory affairs increasingly rewards as the function becomes less about paperwork processing and more about cross-functional risk judgment.
Smith has also spent years contributing to leadership development specifically aimed at women in the industry, serving as an elected leader, invited speaker or sponsor for the SLC Women’s Leadership Conference, the Hillrom Women’s Leadership Network, the BD Women’s Initiative Network and the Bard Access Systems Women’s Leadership Forum across her career. That thread of contribution, running parallel to her operational leadership roles, is part of what she’s now formalizing into a dedicated second act focused on mentorship and advisory work.
Before any of that, Smith’s foundation was built in collegiate athletics. She was an All-American gymnast and a member of the University of Utah’s 1990 NCAA Division I National Championship team, and she credits the discipline and resilience required to compete at that level as directly shaping how she later approached leadership challenges. That athletic scholarship, she has said, was also what made college possible in the first place, having grown up with frequent moves and been raised by a single mother.
Smith’s personal history includes profound loss. She became a single parent herself and, in a tragedy she describes as still ever-present, lost her daughter Maya at age 19. Rather than separating that experience from her professional philosophy, Smith has said it deepened her perspective on perseverance, empathy and the complexity of leading people through difficulty, informing how she led teams as much as her technical expertise did.
That philosophy translates into fairly specific guidance for people early in regulatory and quality careers. Smith consistently advises against chasing titles, emphasizing instead a reputation built on excellent, dependable work and consistent integrity, arguing that careers are long enough for those qualities to compound into opportunity over time. She also pushes back on the idea that effective leadership has to look a particular way, arguing that thoughtful, empathetic and consistent leaders are often more effective than louder, more forceful ones, and that emerging leaders should give themselves permission to fail, since what defines a career is the response to failure rather than its avoidance.
Smith’s read on where the regulatory and quality professions are headed centers heavily on artificial intelligence, a subject with direct relevance to her former field. Medtech regulatory functions are absorbing AI faster than almost any other corner of healthcare technology: the FDA had authorized more than 1,350 AI-enabled medical devices by early 2026, roughly double the number cleared just four years earlier, with the overwhelming majority concentrated in radiology and cardiology applications. That volume has pushed regulators to build new oversight mechanisms specifically for AI-driven products, including predetermined change control plans that let companies pre-authorize how an AI model is allowed to update itself post-market, a departure from the static, one-time-approval model regulatory teams built their careers around.
Smith views that shift as double-edged for the profession she spent decades in. She expects AI to become a critical tool for regulatory and quality work itself, streamlining tasks that have historically consumed enormous specialist time, while acknowledging that organizations will face real challenges determining how to implement and govern that use responsibly. Her broader view is that this creates opportunity rather than obsolescence: regulatory and quality professionals, she argues, are positioned to play an even larger role in bringing new technologies to patients safely as the underlying products themselves grow more complex.
For organizations navigating that same transition, particularly mid-tier medtech companies without the regulatory infrastructure larger competitors have already built for AI-specific compliance, Smith’s advisory and mentorship work offers something increasingly scarce: direct, applied experience translating regulatory complexity into organizational capability, built by someone who spent a career doing exactly that at scale before AI made it more urgent.
Market Landscape
Smith’s transition into advisory work comes as medtech regulatory and quality functions face mounting complexity from multiple directions simultaneously, AI Act obligations in the EU, evolving FDA lifecycle requirements for AI-enabled devices, and the sheer volume of new AI-driven products entering review. As large medtech and life sciences companies continue building AI governance structures often in partnership with major technology and cloud providers, experienced regulatory and quality executives with direct transformation experience are increasingly sought after as advisors and mentors rather than only as internal hires.
Top Insights
- Jessica Smith, PhD, a former senior regulatory and quality executive at Integra LifeSciences, Becton Dickinson, Hillrom and C. R. Bard, is shifting her focus to mentorship and advisory work after a 25-year corporate career.
- Her background combines bioengineering doctoral training with hands-on leadership of global regulatory submissions, quality systems and M&A integration across multinational medtech organizations.
- The FDA had authorized more than 1,350 AI-enabled medical devices by early 2026, nearly double the 2022 total, underscoring the regulatory complexity Smith’s advisory work now addresses.
- Smith has long contributed to women’s leadership development in medtech, supporting initiatives at Hillrom, BD, Bard and independent leadership conferences throughout her career.
- Her leadership philosophy, shaped by collegiate athletics and personal loss, emphasizes authenticity, resilience and leading by example over titles or conformity to a single leadership style.
Join thousands of HR leaders who rely on HRTechEdge for the latest in workforce technology, AI-driven HR solutions, and strategic insights
